Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Average Recommendation of “Moderate Buy” from Analysts
Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the five research firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year […]
Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the five research firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year […]
